{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=77", "query": { "condition": "High-Risk", "page": 77 }, "page_size": 10 }, "pagination": { "page": 77, "page_size": 10, "total_count": 7258, "total_pages": 726, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=78&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=76&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T04:00:00.086Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01742988", "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Relapsed Lymphoma", "Refractory Lymphoma", "Relapsed and/or Refractory Lymphoma", "Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)", "Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "Double-hit Lymphoma (DHL)", "Triple-hit Lymphoma (THL)", "Double-expressor Lymphoma (DEL)", "High-grade B-cell Lymphoma (HGBL)" ], "interventions": [ { "name": "fimepinostat", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2012-12", "completion_date": "2020-10-09", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 11, "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742988" }, { "nct_id": "NCT02559778", "title": "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "sorafenib", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 500, "start_date": "2015-09", "completion_date": "2035-09", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559778" }, { "nct_id": "NCT00537043", "title": "A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "SK&F-105517 (COREG CR FDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2007-10", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2010-10-19", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • Austin, Texas", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00537043" }, { "nct_id": "NCT05413889", "title": "Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Unplanned Hospital Readmissions", "Patients at High Risk of Unplanned Readmission" ], "interventions": [ { "name": "Epic 30-day unplanned readmission risk score", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2023-02-02", "completion_date": "2023-08-17", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413889" }, { "nct_id": "NCT07406490", "title": "Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus (HCV)", "Hepatitis C Virus (HCV) Infection", "HIV (Human Immunodeficiency Virus)" ], "interventions": [ { "name": "Physician-Initiated Screening (Conventional Screening)", "type": "OTHER" }, { "name": "FOCUS (Universal Screening)", "type": "OTHER" }, { "name": "HepC-EnD (Targeted Screening)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 6466, "start_date": "2026-07-01", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 3, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07406490" }, { "nct_id": "NCT03610490", "title": "Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Metastatic Colorectal Adenocarcinoma", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Platinum-Resistant Ovarian Carcinoma", "Recurrent High Grade Ovarian Serous Adenocarcinoma", "Recurrent Ovarian Carcinosarcoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Autologous Tumor Infiltrating Lymphocytes MDA-TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2018-10-16", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2025-04-17", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610490" }, { "nct_id": "NCT03293160", "title": "An Evaluation of the Michigan State Innovation Model in Washtenaw and Livingston Counties", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "High Utilization of Emergency Departments" ], "interventions": [ { "name": "Care management services", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 300, "start_date": "2017-11-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-05-20", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03293160" }, { "nct_id": "NCT03736174", "title": "Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment Syndrome", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Exertional Compartment Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 20, "start_date": "2018-12-07", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-04-25", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03736174" }, { "nct_id": "NCT07281313", "title": "Aphasia Physical EXercise Study: Randomized Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aphasia, Acquired", "Aphasia", "Aphasia, Fluent", "Aphasia, Non-fluent", "Aphasia Following Cerebral Infarction", "Aphasia Following Nontraumatic Intracerebral Hemorrhage" ], "interventions": [ { "name": "High-intensity physical exercise", "type": "BEHAVIORAL" }, { "name": "Low-intensity physical exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, Berkeley", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 120, "start_date": "2025-12-01", "completion_date": "2030-03-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 4, "location_summary": "Berkeley, California • Hayward, California • San Francisco, California", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281313" }, { "nct_id": "NCT05739123", "title": "Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pregnancy Related", "Pregnancy Complications", "Pregnancy, High Risk" ], "interventions": [ { "name": "Relugolix-Containing Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma Switzerland GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "FEMALE", "summary": "0 Years and older · Female only" }, "enrollment_count": 728, "start_date": "2023-05-08", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-11-07T04:00:00.086Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05739123" } ] }